The National Blood Authority is responsible for ensuring the supply of blood and blood products for patient care.
This includes albumin products, which are made using human plasma. They have a range of uses, including in surgery and burns treatment. In Australia, CSL Behring (CSL) manufactures albumin products using plasma collected by Lifeblood from Australian donors.
We fund 2 albumin products under the national blood arrangements. These products are available for patients based on clinical need and appropriate clinical practice.
National Product Price List Plasma and recombinant product supply
The Therapeutic Goods Administration (TGA) regulates blood and blood components(Opens in a new tab/window) as prescription medicines. You can search the Australian Register of Therapeutic Goods(Opens in a new tab/window) for blood and blood products approved for supply in Australia.
Products we fund
Australia's albumin products are in the process of changing as part of the transition of 5 of Australia's domestic plasma products. This was due to CSL upgrading its facilities and processes to expand its capacity.
The transitioned products all comply with the TGA's safety and efficacy requirements.
The new human albumin products are Alburex 5 AU and Alburex 20 AU, with concentrations of 5% (50 g/L) and 20% (200 g/L), respectively. These are replacing Albumex 4 and Albumex 20.
Transition of Australia's domestic plasma products
| Product name | Size |
| Albumex 4 | 50 mL |
| Albumex 4 | 500 mL |
| Albumex 20 | 10 mL |
| Albumex 20 | 100 mL |
| ALBUREX 5 AU | 12.5 g/250 mL |
| ALBUREX 5 AU | 25 g/500 mL |
| ALBUREX 20 AU | 10 g/50 mL |
| ALBUREX 20 AU | 20 g/100 mL |
Get in touch
If you have any queries about albumin products, please contact us.
Last updated: 27 Mar 2024